Financial Performance Summary
Akums Drugs and Pharmaceuticals Ltd. reported consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27), showing strong growth across key metrics.
Revenue Performance:
- Operating revenue: ₹1,167 crore in Q1 FY27
- Year-on-year growth: 13.9% increase from ₹1,024 crore in Q1 FY26
- Quarter-on-quarter performance: Slight increase from ₹1,158 crore in Q4 FY26
Profitability Metrics:
- EBITDA: ₹175 crore in Q1 FY27, representing 35.4% year-on-year growth from ₹129 crore in Q1 FY26
- EBITDA margin: 15.0% in Q1 FY27, improved from 12.6% in Q1 FY26 and 13.1% in Q4 FY26
- PAT: ₹101 crore in Q1 FY27, significant increase from ₹65 crore in Q1 FY26 (55.4% growth)
- PAT margin: 8.4% in Q1 FY27, improved from 6.2% in Q1 FY26 and 6.8% in Q4 FY26
Cost Structure Analysis:
- Cost of goods sold: ₹645 crore in Q1 FY27 (decreased from ₹660 crore in Q4 FY26)
- Employee cost: ₹201 crore in Q1 FY27 (slight increase from ₹199 crore in Q4 FY26)
- Other expenses: ₹145 crore in Q1 FY27 (decreased from ₹147 crore in Q4 FY26)
Segment Performance
The CDMO (Contract Development and Manufacturing Organization) business was the primary growth driver:
- CDMO revenue: ₹964 crore in Q1 FY27, increased from ₹813 crore in Q1 FY26
- CDMO EBITDA: ₹163 crore in Q1 FY27, representing 36.8% year-on-year growth from ₹119 crore in Q1 FY26
- Performance supported by continued volume growth and improvement in API prices
Management Commentary
Mr. Sanjeev Jain, Managing Director, commented: "FY27 has begun on a strong and encouraging note. The consistent performance of CDMO showcases healthy demand environment as well as our clients' trust in Akums as the preferred manufacturing partner."
Mr. Sandeep Jain, Managing Director, added: "We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead."
Financial Results Table
| Particulars (Rs Cr) | Q1 FY 27 | Q4 FY 26 | Q1 FY 26 |
| Revenue | 1,167 | 1,158 | 1,024 |
| Cost of goods sold | 645 | 660 | 582 |
| Employee Cost | 201 | 199 | 176 |
| Other Expenses | 145 | 147 | 137 |
| EBITDA | 175 | 152 | 129 |
| EBITDA Margin | 15.0% | 13.1% | 12.6% |
| PAT | 101 | 81 | 65 |
| PAT Margin | 8.4% | 6.8% | 6.2% |
Key Performance Drivers
- Strong CDMO business momentum with continued volume growth
- Improvement in API prices contributing to margin expansion
- Operational excellence initiatives supporting profitability
- Healthy customer demand environment across business segments